VitaSpring Biomedical (VSBC) Ratios
VitaSpring Biomedical Ratios
VSBC's free cash flow for Q2 2027 was $5.20K. For the 2027 fiscal year, VSBC's free cash flow was increased by $0.00 and operating cash flow was $5.20K. See a summary of the company’s cash flow.
| Ratios | Jan 26 | Jan 25 | Jan 23 | Jan 22 | Jan 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.00 | ― | 0.14 | 1.97 | 2.04 |
| Quick Ratio | 0.00 | ― | 0.14 | 1.97 | 2.04 |
| Cash Ratio | 0.00 | ― | 0.01 | 0.07 | 0.49 |
| Solvency Ratio | -0.09 | ― | -1.25 | 0.63 | -4.57 |
| Operating Cash Flow Ratio | -0.00 | ― | -0.03 | 0.05 | -0.45 |
| Short-Term Operating Cash Flow Coverage | 0.00 | ― | -0.46 | 0.00 | 0.00 |
| Net Current Asset Value | $ -4.43M | ― | $ -2.73M | $ 1.04M | $ 96.36K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | ― | 0.34 | 0.13 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | ― | -0.11 | 0.29 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | ― | -0.12 | 0.23 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | ― | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.00 | ― | -0.32 | 2.28 | 0.49 |
| Debt Service Coverage Ratio | 0.00 | ― | -23.25 | 540.14 | -633.23 |
| Interest Coverage Ratio | 0.00 | ― | 0.00 | 627.59 | -634.90 |
| Debt to Market Cap | 0.00 | ― | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | ― | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.01 | ― | -0.06 | 0.24 | 0.11 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | ― | 0.00% | 36.84% | 45.21% |
| EBIT Margin | 0.00% | ― | 0.00% | 26.43% | -171.12% |
| EBITDA Margin | 0.00% | ― | 0.00% | 26.58% | -170.94% |
| Operating Profit Margin | 0.00% | ― | 0.00% | 26.39% | -171.39% |
| Pretax Profit Margin | 0.00% | ― | 0.00% | 26.39% | -171.39% |
| Net Profit Margin | 0.00% | ― | 0.00% | 22.52% | -171.39% |
| Continuous Operations Profit Margin | 0.00% | ― | 0.00% | 22.52% | -171.39% |
| Net Income Per EBT | 107.77% | ― | 99.87% | 85.34% | 100.00% |
| EBT Per EBIT | 100.00% | ― | 99.81% | 100.00% | 100.00% |
| Return on Assets (ROA) | -2830.25% | ― | -543.69% | 35.07% | -224.60% |
| Return on Equity (ROE) | 9.38% | ― | 173.77% | 80.12% | -109.98% |
| Return on Capital Employed (ROCE) | 8.70% | ― | 181.40% | 72.34% | -441.43% |
| Return on Invested Capital (ROIC) | 8.70% | ― | 195.57% | 61.74% | -109.98% |
| Return on Tangible Assets | -2830.25% | ― | -543.69% | 35.07% | -224.60% |
| Earnings Yield | -0.20% | ― | -0.14% | 0.04% | -0.04% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | ― | 0.00 | 1.90 | 0.00 |
| Payables Turnover | 0.00 | ― | 0.09 | 2.83 | 0.00 |
| Inventory Turnover | 0.00 | ― | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | ― | 0.00 | 10.70 | 0.00 |
| Asset Turnover | 0.00 | ― | 0.00 | 1.56 | 1.31 |
| Working Capital Turnover Ratio | 0.00 | ― | 0.00 | 7.01 | 5.15 |
| Cash Conversion Cycle | -112283.30 | ― | -4012.20 | 63.11 | 0.00 |
| Days of Sales Outstanding | 0.00 | ― | 0.00 | 191.96 | 0.00 |
| Days of Inventory Outstanding | 0.00 | ― | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 112283.30 | ― | 4012.20 | 128.85 | 0.00 |
| Operating Cycle | 0.00 | ― | 0.00 | 191.96 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | ― | -0.00 | 0.00 | -0.00 |
| Free Cash Flow Per Share | -0.00 | ― | -0.00 | 0.00 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | ― | -19389.00 | 1.16 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | ― | -19389.00 | 1.16 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | ― | -0.29 | 0.18 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | ― | 0.00 | 0.02 | -0.17 |
| Free Cash Flow Yield | -0.00% | ― | -0.00% | 0.00% | -0.00% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -500.00 | ― | -740.41 | 2281.47 | -2569.65 |
| Price-to-Sales (P/S) Ratio | 0.00 | ― | 0.00 | 513.75 | 4404.05 |
| Price-to-Book (P/B) Ratio | -46.73 | ― | -1286.62 | 1828.02 | 2826.18 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -77020.10 | ― | -39754.58 | 244098.03 | -25945.51 |
| Price-to-Operating Cash Flow Ratio | -77020.10 | ― | -39756.63 | 34002.36 | -25945.51 |
| Price-to-Earnings Growth (PEG) Ratio | 10.88 | ― | 1.72 | -9.93 | 2.02 |
| Enterprise Value Multiple | -551.41 | ― | -780.57 | 1933.29 | -2576.33 |
| Enterprise Value | 207.03M | ― | 3.08B | 2.88B | 1.09B |
| EV to EBITDA | -551.41 | ― | -780.57 | 1933.29 | -2576.33 |
| EV to Sales | 0.00 | ― | 0.00 | 513.81 | 4403.86 |
| EV to Free Cash Flow | -77019.33 | ― | -39757.58 | 244128.19 | -25944.43 |
| EV to Operating Cash Flow | -77019.33 | ― | -39759.63 | 34006.56 | -25944.43 |
| Tangible Book Value Per Share | -0.02 | ― | -0.01 | 0.01 | 0.00 |
| Shareholders’ Equity Per Share | -0.02 | ― | -0.01 | 0.01 | 0.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.08 | ― | 0.00 | 0.15 | 0.00 |
| Revenue Per Share | 0.00 | ― | 0.00 | 0.03 | 0.00 |
| Net Income Per Share | -0.00 | ― | -0.02 | 0.01 | -0.00 |
| Tax Burden | 1.08 | ― | 1.00 | 0.85 | 1.00 |
| Interest Burden | 1.00 | ― | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | ― | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | ― | 0.00 | 0.10 | 2.16 |
| Stock-Based Compensation to Revenue | 0.00 | ― | 0.00 | 0.03 | 1.75 |
| Income Quality | 0.01 | ― | 0.02 | 0.07 | 0.10 |
Currency in USD
